Monoclonal antibody treatment exposes th
โ
Alasdair J. Coles; Mark G. Wing; Paul Molyneux; Andrea Paolillo; Charlie M. Davi
๐
Article
๐
1999
๐
John Wiley and Sons
๐
English
โ 186 KB
๐ 2 views
The elective treatment of patients with multiple sclerosis, using a humanized anti-leukocyte (CD52) monoclonal antibody (Campath-1H), has illuminated mechanisms that underlie the clinical course of the disease. Twenty-seven patients were studied clinically and by magnetic resonance imaging (MRI) bef